Back to results
US 12,551,582 B2Granted
Granzyme B directed imaging and therapy
AssigneeCytoSite Biopharma Inc.
InventorsJulia Marie Clay, Hui Xiong, Kevin Michael Ruley, Francisco A. Valenzuela, Adam T. Hoye, Mark A. Castanares, James Kronauge
Life of this patent
Estimating the term…
Abstract
Compounds of Formula (I) and Formula (II), which are capable of binding to granzyme B. Also provided herein are pharmaceutical compositions comprising such for use in, for example, imaging Granzyme B and/or treating immunoregulatory abnormalities.
Claims26
A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is of formula (I):
- wherein
- A is a chelating moiety;
- X is selected from the group consisting of —CH2C(NH)—, —CH2C(O)—, —CH2C(S)—, —NHC(NH)—, —NHC(O)—, —NHC(S)—, —OC(NH)—, —OC(O)—, and —OC(S)—, optionally wherein X is —CH2C(O)— or —NHC(S)—;
- L is a peptide linker having 1-6 amino acid residues, inclusive;
- R1 is H or C1-6 alkyl, optionally wherein R1 is H or methyl;
- and
- R2 is C1-6 alkyl or C3-6 cycloalkyl.
4 more elements
A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is of formula (II):
- wherein
- M is a metal or a metal linked to a radioisotope;
- A is a chelating moiety chelating the metal;
- X is selected from the group consisting of —CH2C(NH)—, —CH2C(O)—, —CH2C(S)—, —NHC(NH)—, —NHC(O)—, —NHC(S)—, —OC(NH)—, —OC(O)—, and —OC(S)—, optionally wherein X is —CH2C(NH)— or —NHC(S)—;
- L is a peptide linker having 1-6 amino acid residues, inclusive;
- R1 is H or C1-6 alkyl, optionally wherein R1 is H or methyl;
- and
- R2 is C1-6 alkyl or C3-6 cycloalkyl.
5 more elements
Dependencies are inferred from the claim text.